BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33592015)

  • 1. Beta-blocker and survival in patients with lung cancer: A meta-analysis.
    Lei Z; Yang W; Zuo Y
    PLoS One; 2021; 16(2):e0245773. PubMed ID: 33592015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.
    Li C; Li T; Tang R; Yuan S; Zhang W
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32436935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.
    Wang HM; Liao ZX; Komaki R; Welsh JW; O'Reilly MS; Chang JY; Zhuang Y; Levy LB; Lu C; Gomez DR
    Ann Oncol; 2013 May; 24(5):1312-9. PubMed ID: 23300016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?
    Aydiner A; Ciftci R; Karabulut S; Kilic L
    Asian Pac J Cancer Prev; 2013; 14(10):6109-14. PubMed ID: 24289634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies.
    Lu S; Yu Y; Chen Z; Ye X; Li Z; Niu X
    Lung; 2015 Oct; 193(5):805-14. PubMed ID: 26119960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis.
    Coelho M; Squizzato A; Cassina N; Marino F; Ribeiro LV; Cosentino M
    Eur J Cancer Prev; 2020 Jul; 29(4):306-314. PubMed ID: 31609808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation.
    Hwa YL; Shi Q; Kumar SK; Lacy MQ; Gertz MA; Kapoor P; Buadi FK; Leung N; Dingli D; Go RS; Hayman SR; Gonsalves WI; Russell S; Lust JA; Lin Y; Rajkumar SV; Dispenzieri A
    Am J Hematol; 2017 Jan; 92(1):50-55. PubMed ID: 27733010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
    Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Paz-Ares LG; Zimmermann A; Ciuleanu T; Bunn PA; Antonio BS; Denne J; Iturria N; John W; Scagliotti GV
    Lung Cancer; 2017 Feb; 104():45-51. PubMed ID: 28212999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin improves survival in lung cancer patients with type 2 diabetes mellitus: A meta-analysis.
    Zeng S; Gan HX; Xu JX; Liu JY
    Med Clin (Barc); 2019 Apr; 152(8):291-297. PubMed ID: 30173870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
    Li X; Wang H; Lin W; Xu Q
    Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.